BioCatalyst

Apalutamide, Androgen-deprivation Therapy (ADT) — catalyst calendar

2 verified catalyst event(s) referencing Apalutamide, Androgen-deprivation Therapy (ADT), each linked to its official source. Verified as of 2026-08-06.

Upcoming

DateEventCompanyDrugOfficial source & verification
2026-10-12
in 2mo
ESTIMATED
 READOUT
A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Particip
Phase 3 · Metastatic Castrate-sensitive Prostate Cancer
 Janssen Research & Development, LL Apalutamide, Androgen-deprivation Therap ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
2026-12-01
in 4mo
ESTIMATED
 READOUT
A Study of Apalutamide in Participants With High-Risk, Localized or Locally Adva
Phase 3 · Prostatic Neoplasms
 Janssen Research & Development, LL Apalutamide, Androgen Deprivation Therap ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
Disclaimer. Bio Catalyst Calendar is a public-events data calendar. Every date is sourced and linked to an official record (ClinicalTrials.gov, FDA / Federal Register, openFDA). It is scheduling and reference data only — NOT investment advice, a recommendation, or a buy/sell signal. Dates set by sponsors and the FDA can change; always confirm against the linked official source.